This will play a video - Medical Scientists

leading today transforming tomorrow

OsteoCool™ RF ablation and Kyphon™ balloon kyphoplasty provide treatment options for patients in pain, backed by powerful clinical outcomes.

Osteocool™ RF Ablation — SIR 2021 Abstract of the Year

The OPuS One clinical study of 206 patients demonstrated improvement in pain relief1-2 and quality of life that was:

  • Swift — 3 days post procedure (P < 0.0001)1,2
  • Significant  Improvement at all visits (P < 0.0001 for all visits)1,2
  • Sustained — Long-term improvements through 12 months
    (P < 0.0001 for all visits)1,2

Access 12-month data
OsteoCool RF Ablation Illustration Image
Kyphon™ Balloon Kyphoplasty Illustration Image

Kyphon™ balloon Kyphoplasty For treating VCF

Unmatched commitment to the advancement of a minimally invasive therapy, and to thinking beyond the procedure

  • Powerful evidence — mortality data3-6 and clinically demonstrated pain relief for VCF patients, plus better VCF outcomes than non-surgical management9
  • Flexible — procedural options to meet physician & patient needs 
  • Commitment — 20+ years of treating VCF patients 
  • Standardization — with the VCF Care Pathway 

Find out more


Discover Accurian™ 2.0, complete with responsive algorithms, efficient workflows, an easy-to-use interface, and many more features designed to save steps and time during procedures.

RFA Platform

Request More Information

Would you like to receive additional information about how OsteoCool™ RF Ablation and Kyphon™ Balloon Kyphoplasty are working together to address pain? 

* Indicates a required field.

Your information will be used and protected in accordance with our privacy statement.


Levy J, David E, Hopkins T, et al. Radiofrequency ablation for the palliative treatment of osseous metastases: final results from a multicenter study (OPuS One). Abstract presented at the Society for Interventional Radiology Annual Scientific Meeting. Virtual. 2021.


Levy J, David E, Hopkins T, et al. Improvement in quality of life in patients treated for painful osseous metastases with radiofrequency ablation: The OPuS One Study. Abstract presented at the Society for Interventional Radiology Annual Scientific Meeting. Virtual. 2021.


Ong KL, Beall DP, Frohbergh M, Lau E, Hirsch JA, et al. Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? Osteoporos Int. 2018;29(2):375–383. doi:10.1007/s00198-017-4281-z.


Lange A, Kasperk C, Alvares L, Sauermann S, Braun S. Survival and cost comparison of kyphoplasty and percutaneous vertebroplasty using German claims data. Spine. 2014;39(4): 318-326.


Edidin AA, Ong KL, Lau E, Kurtz SM. Morbidity and mortality after vertebral fractures: comparison of vertebral augmentation and non-operative management in the Medicare population. Spine. 2015;40(15):1228-1241.


Edidin AA, Ong KL, Lau E, Kurtz SM. Mortality risk for operated and non-operated vertebral fracture patients in the Medicare population. J Bone Miner Res. 2011;26(7):1617-1626.


McCullough BJ, Comstock BA, Deyo RA, Kreuter W, Jarvik JG. Major medical outcomes with spinal augmentation versus conservative therapy. JAMA Intern Med. 2013;173(16):1514-1521.


Chen AT, Cohen DB, Skolasky RL. Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the Medicare population. J Bone Joint Surg Am. 2013;95(19):1729-1736.


Boonen S, Van Meirhaeghe J, Bastian L, et al. Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Miner Res. 2011;26(7):1627-1637.


Pre-ablation worst pain was 8.2 decreasing to 5.6 (n=94) at 3 days, 4.7 (n=89) at 1 week, 3.9 (n=64) at 1 month, 3.7 (n=46) at 3 months, and 3.5 (n=22) at 6 months. P<0.0001 all visits.